Prevail Therapeutics Announces Appointment of Morgan Sheng, Ph.D., to Board of Directors

Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced the appointment of Morgan Sheng, Ph.D., to its Board of Directors...
Login to comment.